Initial results from a phase I/II study of BT7480, a novel nectin-4/CD137 bicycle tumor-targeted immune cell agonist, in patients (pts) with advanced solid tumors

Authors
Category Primary study
JournalAnnals of Oncology
Year 2024
This article has no abstract
Epistemonikos ID: 41de1a36b40d2a8c12a13c0c45461c25246e2e7b
First added on: Feb 19, 2025